Targeting alarmins in asthma: From bench to clinic
Journal of Allergy and Clinical Immunology · 2025-04 · 155 (4) · 1133-1148
DOI: 10.1016/j.jaci.2025.01.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-04. Verfasst von Ayobami Akenroye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jeff and Penny Vinik Immunology Center, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Channing Division of…. Hauptthemen laut MEDLINE: Asthma, Alarmins, Anti-Asthmatic Agents. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Over the past 2 decades, mechanistic studies of allergic and type 2 (T2)-mediated airway inflammation have led to multiple approved therapies for the treatment of moderate-to-severe asthma. The approval and availability of these monoclonal antibodies targeting IgE, a T2 cytokine (IL-5) and/or cytokine receptors (IL-5Rα, IL-4Rα) has been central to the progresses made in the management of moderate-to-severe asthma over this period. However, there are persistent gaps in clinician's ability to provide precise care, given that many patients with T2-high asthma do not respond to IgE- or T2 cytokine-targeting therapies and that patients with T2-low asthma have few therapeutic options. The new frontier of precision medicine in asthma, as well as in other allergic diseases, includes the targeting of epithelium-derived cytokines known as alarmins, including thymic stromal lymphopoietin, IL-25, IL-33, and their receptors. The effects of these alarmins, which can act upstream of immune cells, involve both the innate and adaptive systems and hold potential for the treatment of both T2-high and -low disease. Tezepelumab, an anti-thymic stromal lymphopoietin antibody, has already been approved for the treatment of severe asthma. In this review, we discuss our current understanding of alarmin biology with a primary focus on allergic airway diseases. We link the mechanistic corollaries to the clinical implications and advances in drug development targeting alarmins, with a particular focus on currently approved treatments, those under study, and future potential targets in alarmin signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jeff and Penny Vinik Immunology Center, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Mass; Departm…
- Jeff and Penny Vinik Immunology Center, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass.
- Division of Allergy, Asthma and Clinical Immunology, the Department of Medicine, and the Department of Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic Rochester, Rochester, Minn.
Förderung
- NIAID NIH HHS
Zitieren
APA
Akenroye, A., Boyce, J. A., & Kita, H. (2025). Targeting alarmins in asthma: From bench to clinic. Journal of Allergy and Clinical Immunology, 155(4), 1133-1148. https://doi.org/10.1016/j.jaci.2025.01.017
Vancouver
Akenroye A, Boyce JA, Kita H. Targeting alarmins in asthma: From bench to clinic. Journal of Allergy and Clinical Immunology. 2025;155(4):1133-1148. doi:10.1016/j.jaci.2025.01.017
BibTeX
@article{Akenroye2025,
author = {Akenroye, Ayobami and Boyce, Joshua A and Kita, Hirohito},
title = {Targeting alarmins in asthma: From bench to clinic},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {155},
number = {4},
pages = {1133--1148},
doi = {10.1016/j.jaci.2025.01.017}
}
EUVIMED